<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Neural Stimulation on Deep Research</title>
    <link>https://dailydigest.aabot.us/tags/neural-stimulation/</link>
    <description>Recent content in Neural Stimulation on Deep Research</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 May 2026 04:00:00 +0000</lastBuildDate>
    <atom:link href="https://dailydigest.aabot.us/tags/neural-stimulation/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>The $50B Medical Device Revolution: Why Bioelectronic Medicines Must Navigate FDA Mazes Before Replacing Pharmaceuticals</title>
      <link>https://dailydigest.aabot.us/posts/2026-05-11-bioelectronic-medicines-implantable-neural-stimulation-devices-replace-pharmaceuticals-with-precision-electrical-therapy/</link>
      <pubDate>Mon, 11 May 2026 04:00:00 +0000</pubDate>
      <guid>https://dailydigest.aabot.us/posts/2026-05-11-bioelectronic-medicines-implantable-neural-stimulation-devices-replace-pharmaceuticals-with-precision-electrical-therapy/</guid>
      <description>Bioelectronic medicine demonstrates remarkable clinical outcomes—vagus nerve stimulation reduces inflammatory cytokines by 40%, spinal cord stimulators provide sustained pain relief for medication-resistant conditions, and deep brain stimulation transforms Parkinson&amp;rsquo;s treatment. Yet scaling these breakthrough devices from research successes to widespread patient access requires navigating complex FDA approval pathways, clinical trial designs, and reimbursement frameworks that determine whether electrical therapy replaces pharmaceuticals or remains confined to specialized medical centers.</description>
    </item>
  </channel>
</rss>
